Tenax Therapeutics
Healthcare · 4 employees
Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company focused on developing and commercializing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with a current focus on pulmonary hypertension.
Funding history
- Funding Round — $99.7M — Aug 2024
- Funding Round — $8.0M — Jun 2022
- Funding Round — $10.0M — Jul 2021
- Funding Round — $5.2M — Jul 2020
- Series seed — $317K — Mar 2020
Recent signals
- Apr 22, 2026: Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
- Aug 23, 2024: Raised $99.7M
- Aug 12, 2024: Tenax Therapeutics Announces $100 Million Private Placement and Plans to Accelerate Oral Levosimendan Phase 3 Program
- Jun 01, 2022: Raised $8.0M
- Jul 20, 2021: Raised $10.0M
- Jul 22, 2020: Raised $5.2M
- Mar 27, 2020: Raised $317K in Series seed
See plans & pricing → Track Tenax Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.